Antabio Receives QIDP Designation from the U.S. FDA for the Development of Its Metallo Beta-Lactamase inhibitor ANT2681

Antabio’s Novel Metallo β-Lactamase Inhibitor to be presented at the ASM Microbe Conference, June 20-24, San Francisco

Marc Lemonnier appointed at the Scientific Advisory Board of JPIAMR

ANTABIO Completes € 12.5M Series A

First publication from Antabio’s novel metallo-β-lactamase (MBL) inhibitor program

ANTABIO Announces Key Executive Appointments

ANTABIO raises € 7.3M Series A Financing to Develop Novel Treatments against Drug-Resistant Gram-negative infections

ANTABIO awarded up to $8.9M from CARB-X to accelerate the development of its new treatment for chronic infections in Cystic Fibrosis patients

Marc Lemonnier elected at the Board of the BEAM Alliance

Antabio receives the BIOVISION 2016 Investor Conference Biotech Award